Trials / Completed
CompletedNCT07418203
Knowledge of 18-19 Years Old About Papillomavirus and HPV Vaccination
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 29 (actual)
- Sponsor
- Université de Reims Champagne-Ardenne · Academic / Other
- Sex
- All
- Age
- 18 Years – 19 Years
- Healthy volunteers
- Accepted
Summary
Today, cancers associated with papillomavirus infection affect 6,300 new people each year in France, men and women combined. The papillomavirus vaccine is currently the only vaccine that protects against HPV-associated cancers. However, in its report on vaccination coverage for 2024, Santé Publique France reveals that 41.5% and 37.4% of the 18- and 19-year-old French population respectively have a complete vaccination schedule. Information, education and communication about HPV are essential to enable the entire population to make informed and responsible decisions about HPV. Increasing information and immunization coverage for papillomavirus is part of the government's ambitious health plans with the national sexual health strategy and college vaccination campaign.
Detailed description
The main objective is to describe knowledge of girls and boys aged 18-19 about papillomavirus and HPV vaccination
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Data collection | Data collection |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2025-02-01
- Completion
- 2025-07-01
- First posted
- 2026-02-18
- Last updated
- 2026-02-18
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT07418203. Inclusion in this directory is not an endorsement.